Physical Medicine and Rehabilitation for Complex Regional Pain Syndromes Medication
- Author: Manish K Singh, MD; Chief Editor: Stephen Kishner, MD, MHA more...
Multiple classes of medications have been tried for patients with CRPS, often with variable results and generally with limited published research to help clinicians predict which patients will respond well to a particular medication.
Analgesic drug therapy for CRPS can be divided into the following categories:
- Opioids are used commonly as an analgesic for many pain syndromes.
- Opioid therapy can be a safe and good option in patients with intractable nonmalignant pain and no history of drug abuse.
- Quang-Cantagrel and colleagues reported that failure of one opioid cannot predict the patient's response to another opioid.
- High doses of tramadol may provide effective and safe relief in neuropathic pain, including allodynia.
Nonopioid analgesics (eg, NSAIDs, acetaminophen)
- Acetaminophen is a safe choice for treatment of pain during pregnancy and breastfeeding.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are discussed in further detail within the tables below.
Antidepressant medications play a major role in treatment of neuropathic pain.
- Tricyclic antidepressants:
- Amitriptyline (Elavil)
- Imipramine (Tofranil)
- Doxepin (Sinequan)
- Clomipramine (Anafranil)
- Nortriptyline (Pamelor)
- Selective serotonin reuptake inhibitor (SSRI) antidepressants:
- Paroxetine (Paxil)
- Fluoxetine (Prozac)
- Sertraline (Zoloft)
- Escitalopram (Lexapro)
- Other antidepressants:
- Nefazodone (Serzone)
- Venlafaxine (Effexor)
- Duloxetine (Cymbalta)
- Bupropion (Wellbutrin)
- Sodium channel antagonists have been used in the management of neuropathic pain for several years.
- These medications are started slowly and are administered as needed.
- The patient is monitored carefully.
- Use of several anticonvulsant drugs (eg, pregabalin, carbamazepine, phenytoin, sodium valproate, clonazepam, topiramate, lamotrigine) has been tried in the treatment of RSD.
- In studies by Nicholson and by Rowbothan and colleagues, gabapentin has been reported to be effective in the management of chronic neuropathic pain syndromes.
- Controlled studies for the effect of lamotrigine have not become available yet, but Jain notes that the drug has shown effect in neuropathic pain.
- Ziconotide may be useful in the future for neuropathic pain, as Jain notes that it has a favorable risk/benefit ratio, with advantages over several currently available intrathecal therapies for pain.
Other adjunct analgesics
- Hewitt states that N -methyl-D-aspartate (NMDA) – receptor antagonists, including ketamine and dextromethorphan, may have potential as co-analgesics when used in combination with opioids. Some studies have shown that ketamine infusion therapy provides effective pain relief and does not have adverse cognitive effects with extended use.[33, 34]
- Benzodiazepines, baclofen, and tizanidine may be helpful in decreasing spasm and providing pain relief.
- Corticosteroid, mexiletine (orally active class Ib anti-arrhythmic agent), nifedipine (calcium channel blocker), propranolol (beta blocker), phenoxybenzamine (alpha blocker), and clonidine (alpha2-adrenergic agonist) are other alternatives. Some drug trials provided consistent support for analgesia with corticosteroids in the early stage and may have long-term effectiveness.
- Lidoderm 5% patches are sometimes helpful in decreasing allodynia and providing pain relief.
- Although it has not been approved by the Food and Drug Administration (FDA) for this indication, botulinum toxin can be considered for dystonia seen in patients with RSD.
Nonsteroidal anti-inflammatory drugs
These inhibit inflammatory reactions and pain by decreasing activity of cyclo-oxygenase, which is responsible for prostaglandin synthesis. NSAIDs may provide pain relief in the early stage of RSD.
NSAIDs are used commonly for patients with mild to moderate pain. Inhibit inflammatory reactions and pain by decreasing prostaglandin synthesis.
For relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing activity of cyclo-oxygenase, which results in a decrease of prostaglandin synthesis.
These drugs increase the synaptic concentration of serotonin and/or norepinephrine in the CNS by inhibiting their re-uptake by the presynaptic neuronal membrane. Similar agents that can be helpful are duloxetine (Cymbalta) and venlafaxine (Effexor).
Has demonstrated effectiveness in the treatment of chronic and neuropathic pain.
Has demonstrated effectiveness in certain chronic and neuropathic pain.
Indicated for diabetic peripheral neuropathic pain. Potent inhibitor of neuronal serotonin and norepinephrine reuptake.
Use of certain anti-epileptic drugs, such as the GABA analogue gabapentin (Neurontin), has proven helpful in some cases of neuropathic pain. Other anticonvulsant drugs (eg, carbamazepine, phenytoin, sodium valproate or clonazepam, topiramate, lamotrigine, zonisamide, tiagabine) also have been tried in RSD.
Has anticonvulsant properties and antineuralgic effects; however, exact mechanism of action is unknown. Structurally related to GABA but does not interact with GABA receptors.
Structural derivative of GABA. Mechanism of action unknown. Binds with high affinity to alpha 2 -delta site (a calcium channel subunit). In vitro, reduces calcium-dependent release of several neurotransmitters, possibly by modulating calcium channel function. FDA approved for neuropathic pain associated with diabetic peripheral neuropathy or postherpetic neuralgia and as adjunctive therapy in partial-onset seizures.
These commonly used analgesics are employed for many pain syndromes.
Currently, the long-acting form of opioids is commonly used in initial and later stages of RSD. Start with a small dose and increase gradually.
DOC for analgesia due to reliable and predictable effects, safety profile, and ease of reversibility with naloxone. Various IV doses are used; commonly titrated until desired effect obtained.
Potent narcotic analgesic with much shorter half-life than morphine sulfate. Excellent choice for pain management and sedation with short duration (30-60 min) and easy to titrate. Easily and quickly reversed by naloxone.
When using transdermal dosage form, most patients are controlled with 72 h dosing intervals; however, some patients may require dosing intervals of 48 h.
Uceyler N, Eberle T, Rolke R, et al. Differential expression patterns of cytokines in complex regional pain syndrome. Pain. Sep 2007. [Medline].
Wasner G, Heckmann K, Maier C, et al. Vascular abnormalities in acute reflex sympathetic dystrophy (CRPS I): complete inhibition of sympathetic nerve activity with recovery. Arch Neurol. 1999 May. 56(5):613-20. [Medline]. [Full Text].
Kurvers HA, Jacobs MJ, Beuk RJ, et al. The spinal component to skin blood flow abnormalities in reflex sympathetic dystrophy. Arch Neurol. 1996 Jan. 53(1):58-65. [Medline].
Blaes F, Tschernatsch M, Braeu ME, Matz O, Schmitz K, Nascimento D. Autoimmunity in complex-regional pain syndrome. Ann N Y Acad Sci. 2007 Jun. 1107:168-73. [Medline].
Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet. 1993 Oct 23. 342(8878):1012-6. [Medline].
Maleki J, LeBel AA, Bennett GJ, et al. Patterns of spread in complex regional pain syndrome, type I (reflex sympathetic dystrophy). Pain. 2000 Dec 1. 88(3):259-66. [Medline].
Peterlin BL, Rosso AL, Nair S, et al. Migraine may be a risk factor for the development of complex regional pain syndrome. Cephalalgia. 2009 Jul 9. [Medline].
Werner R, Davidoff G, Jackson MD, et al. Factors affecting the sensitivity and specificity of the three-phase technetium bone scan in the diagnosis of reflex sympathetic dystrophy syndrome in the upper extremity. J Hand Surg [Am]. 1989 May. 14(3):520-3. [Medline].
Schürmann M, Zaspel J, Löhr P, et al. Imaging in early posttraumatic complex regional pain syndrome: a comparison of diagnostic methods. Clin J Pain. 2007 Jun. 23(5):449-57. [Medline].
Bruehl S, Lubenow TR, Nath H, Ivankovich O. Validation of thermography in the diagnosis of reflex sympathetic dystrophy. Clin J Pain. 1996 Dec. 12(4):316-25. [Medline].
Chelimsky TC, Low PA, Naessens JM, et al. Value of autonomic testing in reflex sympathetic dystrophy. Mayo Clin Proc. 1995 Nov. 70(11):1029-40. [Medline].
Brunnekreef JJ, Oosterhof J, Wolff AP, et al. No impaired hemoglobin oxygenation in forearm muscles of patients with chronic CRPS-1. Clin J Pain. 2009 Jul-Aug. 25(6):513-9. [Medline].
[Guideline] Harden RN, Oaklander AL, Burton AW, et al. Complex regional pain syndrome: practical diagnostic and treatment guidelines, 4th edition. Pain Med. 2013 Feb. 14(2):180-229. [Medline]. [Full Text].
Rashiq S, Galer BS. Proximal myofascial dysfunction in complex regional pain syndrome: a retrospective prevalence study. Clin J Pain. 1999 Jun. 15(2):151-3. [Medline].
Steverens VL, Oerlemans HM, Weesels A. Cost effectiveness analysis of adjuring physical or occupational therapy for patients with RSD. Arch Phys Med Rehabilitation. 1999. 80:1038-43.
Johnston EC, Howell SJ. Tension neuropathy of the superficial peroneal nerve: associated conditions and results of release. Foot Ankle Int. 1999 Sep. 20(9):576-82. [Medline].
Eckmann MS, Ramamurthy S, Griffin JG. Intravenous regional ketorolac and lidocaine in the treatment of complex regional pain syndrome of the lower extremity: a randomized, double-blinded, crossover study. Clin J Pain. 2011 Mar-Apr. 27(3):203-6. [Medline].
Kumar K, Nath RK, Toth C. Spinal cord stimulation is effective in the management of reflex sympathetic dystrophy. Neurosurgery. 1997 Mar. 40(3):503-8; discussion 508-9. [Medline].
Geurts JW, Smits H, Kemler MA, et al. Spinal cord stimulation for complex regional pain syndrome type I: a prospective cohort study with long-term follow-up. Neuromodulation. 2013 Nov-Dec. 16(6):523-9; discussion 529. [Medline].
van Hilten BJ, van de Beek WJ, Hoff JI, et al. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med. 2000 Aug 31. 343(9):625-30. [Medline]. [Full Text].
Lundborg C, Dahm P, Nitescu P, et al. Clinical experience using intrathecal (IT) bupivacaine infusion in three patients with complex regional pain syndrome type I (CRPS-I). Acta Anaesthesiol Scand. 1999 Jul. 43(6):667-78. [Medline].
Monti DA, Herring CL, Schwartzman RJ, et al. Personality assessment of patients with complex regional pain syndrome type I. Clin J Pain. 1998 Dec. 14(4):295-302. [Medline].
Hassenbusch SJ, Stanton-Hicks M, Schoppa D, et al. Long-term results of peripheral nerve stimulation for reflex sympathetic dystrophy. J Neurosurg. 1996 Mar. 84(3):415-23. [Medline].
Zollinger PE, Tuinebreijer WE, Breederveld RS, et al. Can vitamin C prevent complex regional pain syndrome in patients with wrist fractures? A randomized, controlled, multicenter dose-response study. J Bone Joint Surg Am. 2007 Jul. 89(7):1424-31. [Medline].
Mbizvo GK, Nolan SJ, Nurmikko TJ, et al. Placebo Responses in Long-Standing Complex Regional Pain Syndrome: A Systematic Review and Meta-Analysis. J Pain. 2015 Feb. 16(2):99-115. [Medline].
Hsu ES. Practical management of complex regional pain syndrome. Am J Ther. 2009 Mar-Apr. 16(2):147-54. [Medline].
Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth Analg. 2000 Apr. 90(4):933-7. [Medline]. [Full Text].
Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998 Dec 2. 280(21):1837-42. [Medline].
Jain KK. An evaluation of intrathecal ziconotide for the treatment of chronic pain. Expert Opin Investig Drugs. 2000 Oct. 9(10):2403-10. [Medline].
Kiefer RT, Rohr P, Ploppa A, et al. Complete recovery from intractable complex regional pain syndrome, CRPS-type I, following anesthetic ketamine and midazolam. Pain Pract. 2007 Jun. 7(2):147-50. [Medline].
Koffler SP, Hampstead BM, Irani F, et al. The neurocognitive effects of 5 day anesthetic ketamine for the treatment of refractory complex regional pain syndrome. Arch Clin Neuropsychol. 2007 Aug. 22(6):719-29. [Medline].
Dumitru D. Reflex sympathetic dystrophy. Phys Med Rehabil: State Art Rev. 1991. 5:89-101.
Baron R. Peripheral neuropathic pain: from mechanisms to symptoms. Clin J Pain. 2000 Jun. 16(2 Suppl):S12-20. [Medline].
Baron R, Maier C. Reflex sympathetic dystrophy: skin blood flow, sympathetic vasoconstrictor reflexes and pain before and after surgical sympathectomy. Pain. 1996 Oct. 67(2-3):317-26. [Medline].
Bhatia KP, Bhatt MH, Marsden CD. The causalgia-dystonia syndrome. Brain. 1993 Aug. 116 ( Pt 4):843-51. [Medline].
Blanchard J, Ramamurthy S, Walsh N, et al. Intravenous regional sympatholysis: a double-blind comparison of guanethidine, reserpine, and normal saline. J Pain Symptom Manage. 1990 Dec. 5(6):357-61. [Medline].
Brown DL. Somatic or sympathetic block for reflex sympathetic dystrophy. Which is indicated?. Hand Clin. 1997 Aug. 13(3):485-97. [Medline].
Bruehl S, Harden RN, Galer BS, et al. External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria. International Association for the Study of Pain. Pain. 1999 May. 81(1-2):147-54. [Medline].
Clinchot DM, Lorch F. Sympathetic skin response in patients with reflex sympathetic dystrophy. Am J Phys Med Rehabil. 1996 Jul-Aug. 75(4):252-6.
Cohen JS. Erythromelalgia: new theories and new therapies. J Am Acad Dermatol. 2000 Nov. 43(5 Pt 1):841-7. [Medline].
Galer BS, Bruehl S, Harden RN. IASP diagnostic criteria for complex regional pain syndrome: a preliminary empirical validation study. International Association for the Study of Pain. Clin J Pain. 1998 Mar. 14(1):48-54. [Medline].
Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005 Jul. 116(1-2):109-18. [Medline].
Harden RN. A clinical approach to complex regional pain syndrome. Clin J Pain. 2000 Jun. 16(2 Suppl):S26-32. [Medline].
Hewitt DJ. The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain. 2000 Jun. 16(2 Suppl):S73-9. [Medline].
Hopp J, Schwartzman RJ, Grothusen J. Increased sensory thresholds in patients with reflex sympathetic dystrophy. Neurology. Feb 1996. 46 A:227.
Hord ED, Oaklander AL. Complex regional pain syndrome: a review of evidence-supported treatment options. Curr Pain Headache Rep. 2003 Jun. 7(3):188-96. [Medline].
Kemler MA, van de Vusse AC, van den Berg-Loonen EM, et al. HLA-DQ1 associated with reflex sympathetic dystrophy. Neurology. 1999 Oct 12. 53(6):1350-1. [Medline].
Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain. 1997 Nov. 73(2):123-39. [Medline].
Kurvers HA, Jacobs MJ, Beuk RJ, et al. Reflex sympathetic dystrophy: evolution of microcirculatory disturbances in time. Pain. 1995 Mar. 60(3):333-40. [Medline].
Linson MA, Leffert R, Todd DP. The treatment of upper extremity reflex sympathetic dystrophy with prolonged continuous stellate ganglion blockade. J Hand Surg [Am]. 1983 Mar. 8(2):153-9. [Medline].
Merskey H, Bogduk N. Classification of Chronic Pain, Description of Chronic Pain Syndrome and Definitions of Pain Terms. Seattle, Wash: IASP Press; 1994.
Norton JV, Zager E, Grady JF. Erythromelalgia: diagnosis and classification. J Foot Ankle Surg. 1999 May-Jun. 38(3):238-41. [Medline].
Ochoa JL. Reflex sympathetic dystrophy: a disease of medical understanding. Clin J Pain. 1992 Dec. 8(4):363-6; discussion 367-9. [Medline].
Pak TJ, Martin GM, Magness JL, et al. Reflex sympathetic dystrophy. Review of 140 cases. Minn Med. 1970 May. 53(5):507-12. [Medline].
Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain. 1986 May. 25(2):171-86. [Medline].
Rommel O, Tegenthoff M, Pern U, et al. Sympathetic skin response in patients with reflex sympathetic dystrophy. Clin Auton Res. 1995 Sep. 5(4):205-10. [Medline].
Schwartzman RJ. Explaining reflex sympathetic dystrophy. Arch Neurol. 1999 May. 56(5):521-2. [Medline].
Schwartzman RJ. New treatments for reflex sympathetic dystrophy. N Engl J Med. 2000 Aug 31. 343(9):654-6. [Medline].
Schwartzman RJ, Kerrigan J. The movement disorder of reflex sympathetic dystrophy. Neurology. 1990 Jan. 40(1):57-61. [Medline].
Schwartzman RJ, Liu JE, Smullens SN, et al. Long-term outcome following sympathectomy for complex regional pain syndrome type 1 (RSD). J Neurol Sci. 1997 Sep 10. 150(2):149-52. [Medline].
Schwartzman RJ, Maleki J. Postinjury neuropathic pain syndromes. Med Clin North Am. 1999 May. 83(3):597-626. [Medline].
Stanton-Hicks M, Baron R, Boas R, et al. Complex regional pain syndromes: guidelines for therapy. Clin J Pain. 1998 Jun. 14(2):155-66. [Medline].
Stanton-Hicks M, Janig W, Hassenbusch S, et al. Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain. 1995 Oct. 63(1):127-33. [Medline].
Tahmoush AJ, Schwartzman RJ, Hopp JL, et al. Quantitative sensory studies in complex regional pain syndrome type 1/RSD. Clin J Pain. 2000 Dec. 16(4):340-4. [Medline].
van der Laan L, Veldman PH, Goris RJ. Severe complications of reflex sympathetic dystrophy: infection, ulcers, chronic edema, dystonia, and myoclonus. Arch Phys Med Rehabil. 1998 Apr. 79(4):424-9. [Medline].
Wasner G, Backonja MM, Baron R. Traumatic neuralgias: complex regional pain syndromes (reflex sympathetic dystrophy and causalgia): clinical characteristics, pathophysiological mechanisms and therapy. Neurol Clin. 1998 Nov. 16(4):851-68. [Medline].
Wechsler RJ, Frank ED, Halpern EH, et al. Percutaneous lumbar sympathetic plexus catheter placement for short- and long-term pain relief: CT technique and results. J Comput Assist Tomogr. 1998 Jul-Aug. 22(4):518-23. [Medline].
Wilder RT, Berde CB, Wolohan M, et al. Reflex sympathetic dystrophy in children. Clinical characteristics and follow-up of seventy patients. J Bone Joint Surg Am. 1992 Jul. 74(6):910-9. [Medline].
Zollinger PE, Tuinebreijer WE, Kreis RW, et al. Effect of vitamin C on frequency of reflex sympathetic dystrophy in wrist fractures: a randomised trial. Lancet. 1999 Dec 11. 354(9195):2025-8. [Medline].